In summary, our data suggest that monthly rituximab 100 mg appeared as a potential effective regimen for treating anti-PLA2R-associated primary membranous nephropathy with a low anti-PLA2R titer, especially suitable for a certain subset of patients, such as the elderly, those susceptible to infection, and patients with limited financial resources. This evidence concerns the gene PLA2R1 and infection.